Almac Announce Launch of Next Generation Sequencing (NGS) Data Analysis Services

Almac Announce Launch of Next Generation Sequencing (NGS) Data Analysis Services

February 01, 2012

CRAIGAVON, Northern Ireland--(BUSINESS WIRE)--Almac's Diagnostics business unit today announced launch of its advanced Next Generation Sequencing (NGS) data Analysis services.

These latest enhancements to Almac's service portfolio include a comprehensive range of NGS solutions from professional study design to sample processing and expert data analysis for DNA and RNA samples. Uniquely, the services are highly customizable and are available on a standalone basis or in combination with Almac's established bioinformatics offerings in the areas of biological analysis, biomarker and drug discovery and development and diagnostic product development. Almac will utilize the latest sequencing technologies and most sophisticated modern computational analysis techniques to ensure optimal results from customer data.

The solutions are delivered through a large and experienced bioinformatics team from a wide range of disciplines including biology, medicine, mathematics and biostatistics. In addition to the team's expertise in bioinformatics and biostatistics they also have substantial experience in molecular and cell biology, drug discovery and development, and diagnostic product development.

Michael Sloan, Vice President of Business Development for Almac said:

"NGS is a rapidly maturing technology that continues to demonstrate significant benefits over traditional methods as well as making substantial steps toward routine use in the clinical setting. By expanding our services to include this range of DNA and RNA-Seq analysis we are empowering our customers with the most cutting edge technologies, opening new avenues within their research and boosting the potential for advancement of human health in a variety of disease settings".

Almac's NGS services build upon long standing expertise in the application of cutting edge technology to the improvement of human health.

Notes to Editors

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.

Contacts

De Facto Communications
Tristan Jervis
[email protected]
T: +44 207 861 3019
M: +44 771 363 8396
or
Almac
Michael Sloan
[email protected]
T: +44 28 3833 7575

 

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.